Acute pericarditis: Update on diagnosis and management

Research output: Contribution to journalReview articlepeer-review

24 Citations (Scopus)

Abstract

Acute pericarditis accounts for ∼5% of presentations with acute chest pain. Tuberculosis is an important cause in the developing world, however, in the UK and other developed settings, most cases are idiopathic/viral in origin. Non-steroidal anti-inflammatory drugs (NSAIDs) remain the cornerstone of treatment. At least one in four patients are at risk of recurrence. The addition of 3 months of colchicine can more than halve the risk of this (number needed to treat = four). Low-dose steroids can be helpful second-line agents for managing recurrences as adjuncts to NSAIDs and colchicine but should not be used as first-line agents. For patients failing this approach and/or dependent on corticosteroids, the interleukin-1β antagonist anakinra is a promising option, and for the few patients who are refractory to medical therapy, surgical pericardiectomy can be considered. The long-term prognosis is good with <0.5% risk of constriction for patients with idiopathic acute pericarditis.

Original languageEnglish
Pages (from-to)48-51
Number of pages4
JournalClinical medicine (London, England)
Volume20
Issue number1
DOIs
Publication statusPublished - Jan 2020

Keywords

  • Pericarditis
  • chest pain
  • colchicine
  • constriction
  • pericardiectomy

Fingerprint

Dive into the research topics of 'Acute pericarditis: Update on diagnosis and management'. Together they form a unique fingerprint.

Cite this